Ceregene - Newsroom

Press Releases

05.21.13	Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
04.19.13	Ceregene Reports Data From Parkinson's Disease Phase 2b Study
03.13.13	Ceregene and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial
05.17.12	Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
05.09.12	Parkinson's Disease therapeutics focal point at this year's ASGCT meeting
12.01.11	Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease
02.15.11	Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors
02.03.11	Ceregene Advances Phase2b CERE-120 (AAV2-Neurturin) Trial in Parkinson's Disease
11.11.10	Ceregene Raises $11.5 Million in Series D Financing
10.19.10	Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
06.22.10	The Michael J. Fox Foundation Awards $2.5 Million to Support Ceregene's New Phase 2 Neurturin Clinical Study for Parkinson's Disease
04.28.10	Ceregene Has Initiated a New Phase 1/2 Trial of CERE-120 for Parkinson's Disease
08.05.09	Ceregene Receives Additional Grant from Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
05.27.09	Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
11.26.08	Ceregene Announces Clinical Data from Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
11.04.08	Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant from National Institutes of Health
04.23.08	Ceregene Announces Two Key Additions to Leadership Team
01.07.08	Ceregene to Present at JPMorgan 26th Annual Healthcare Conference
12.12.07	Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson's Disease
12.06.07	Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
11.14.07	Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
06.21.07	Ceregene and Genzyme Announce Partnership for the Development and Commercialization of CERE-120 for Parkinson's Disease
05.02.07	Ceregene Presents Interim Phase I Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
04.16.07	Ceregene Presents Long Term Follow-Up Data from Phase I Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients
04.13.07	Growth Factor Therapy Appears to Improve Symptoms in Mid-Stage Parkinson's Disease

Archived Press Releases:

2006 | 2005 | 2004 | 2003 | 2002 | 2001